CACNA1S Gene Malignant Hyperthermia Type 5 Genetic Test
Test Name: CACNA1S Gene Malignant Hyperthermia Type 5 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CACNA1S Gene Malignant Hyperthermia Type 5.
Test Details
The CACNA1S gene is associated with a condition called malignant hyperthermia type 5. Malignant hyperthermia is a rare, life-threatening reaction to certain medications used during general anesthesia. It is characterized by a rapid increase in body temperature, muscle rigidity, and other symptoms.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that can analyze multiple genes simultaneously. In the case of malignant hyperthermia type 5, NGS genetic testing can be used to identify mutations or variations in the CACNA1S gene that may be associated with the condition.
By analyzing the individual’s DNA, NGS genetic testing can provide information about the presence or absence of specific genetic variations that may increase the risk of developing malignant hyperthermia. This information can be used to diagnose the condition, assess the risk of an adverse reaction to anesthesia, and guide treatment decisions.
It is important to note that NGS genetic testing for malignant hyperthermia type 5 is typically performed in individuals with a suspected or confirmed diagnosis of malignant hyperthermia or a family history of the condition. The test is usually ordered by a healthcare provider who specializes in genetics or anesthesiology.
| Test Name | CACNA1S Gene Malignant hyperthermia type 5 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CACNA1S Gene Malignant hyperthermia type 5 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CACNA1S Gene Malignant hyperthermia type 5 |
| Test Details | The CACNA1S gene is associated with a condition called malignant hyperthermia type 5. Malignant hyperthermia is a rare, life-threatening reaction to certain medications used during general anesthesia. It is characterized by a rapid increase in body temperature, muscle rigidity, and other symptoms. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that can analyze multiple genes simultaneously. In the case of malignant hyperthermia type 5, NGS genetic testing can be used to identify mutations or variations in the CACNA1S gene that may be associated with the condition. By analyzing the individual’s DNA, NGS genetic testing can provide information about the presence or absence of specific genetic variations that may increase the risk of developing malignant hyperthermia. This information can be used to diagnose the condition, assess the risk of an adverse reaction to anesthesia, and guide treatment decisions. It is important to note that NGS genetic testing for malignant hyperthermia type 5 is typically performed in individuals with a suspected or confirmed diagnosis of malignant hyperthermia or a family history of the condition. The test is usually ordered by a healthcare provider who specializes in genetics or anesthesiology. |
